CorMedix Inc. to Present at the Cantor Global Healthcare Conference
CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company, has announced its participation in the 2024 Cantor Global Healthcare Conference in New York, NY from September 17-19, 2024. The company's management will engage in a fireside chat on Thursday, September 19, 2024, at 10:55 AM EDT, along with one-on-one investor meetings.
The event provides an opportunity for CorMedix to showcase its focus on developing and commercializing therapeutic products for preventing and treating life-threatening conditions and diseases. Investors and interested parties can access a live webcast of the fireside chat through a provided link, with a replay available later on the company's website under the 'Events and Presentations' section.
CorMedix Inc. (Nasdaq: CRMD), un'azienda biofarmaceutica, ha annunciato la sua partecipazione alla 2024 Cantor Global Healthcare Conference a New York, NY, dal 17 al 19 settembre 2024. Il management dell'azienda parteciperà a un incontro informale giovedì 19 settembre 2024, alle 10:55 AM EDT, oltre a incontri individuali con gli investitori.
L'evento offre l'opportunità a CorMedix di mettere in evidenza il proprio impegno nello sviluppo e nella commercializzazione di prodotti terapeutici per la prevenzione e il trattamento di condizioni e malattie potenzialmente letali. Gli investitori e le parti interessate possono accedere a un webcast in diretta dell'incontro informale attraverso un link fornito, con una registrazione disponibile successivamente sul sito web dell'azienda nella sezione 'Eventi e Presentazioni'.
CorMedix Inc. (Nasdaq: CRMD), una empresa biofarmacéutica, ha anunciado su participación en la Conferencia de Atención Médica Global Cantor 2024 en Nueva York, NY, del 17 al 19 de septiembre de 2024. La dirección de la empresa participará en una charla informal el jueves 19 de septiembre de 2024, a las 10:55 AM EDT, junto con reuniones individuales con inversores.
Este evento brinda a CorMedix la oportunidad de mostrar su enfoque en el desarrollo y la comercialización de productos terapéuticos para prevenir y tratar condiciones y enfermedades potencialmente mortales. Los inversores y partes interesadas pueden acceder a un webcast en vivo de la charla informal a través de un enlace proporcionado, con una repetición disponible más tarde en el sitio web de la empresa en la sección 'Eventos y Presentaciones'.
CorMedix Inc. (Nasdaq: CRMD)는 생명공학 제약회사로, 2024년 9월 17일부터 19일까지 뉴욕에서 열리는 2024 Cantor Global Healthcare Conference에 참석한다고 발표했습니다. 회사 경영진은 2024년 9월 19일 목요일 오전 10:55 EDT에 파이어사이드 챗에 참여하며, 개별 투자자 회의도 가질 예정입니다.
이 행사는 CorMedix가 생명을 위협하는 질병과 상태를 예방하고 치료하기 위한 치료 제품 개발 및 상용화에 집중하고 있음을 보여줄 수 있는 기회를 제공합니다. 투자자와 관심 있는 사람들은 제공된 링크를 통해 실시간 웹캐스트에 접근할 수 있으며, 이후 회사 웹사이트의 '이벤트 및 발표' 섹션에서 다시 볼 수 있습니다.
CorMedix Inc. (Nasdaq: CRMD), une entreprise biopharmaceutique, a annoncé sa participation à la Conférence mondiale sur les soins de santé Cantor 2024 à New York, NY, du 17 au 19 septembre 2024. La direction de l'entreprise participera à un échange informel le jeudi 19 septembre 2024, à 10h55 EDT, en plus de réunions individuelles avec des investisseurs.
Cette événement représente une opportunité pour CorMedix de mettre en avant son engagement dans le développement et la commercialisation de produits thérapeutiques destinés à prévenir et traiter des conditions et maladies potentiellement mortelles. Les investisseurs et les parties intéressées peuvent accéder à un webcast en direct de l'échange informel via un lien fourni, avec une rediffusion disponible ultérieurement sur le site web de l'entreprise dans la section 'Événements et présentations'.
CorMedix Inc. (Nasdaq: CRMD), ein biopharmazeutisches Unternehmen, hat seine Teilnahme an der 2024 Cantor Global Healthcare Conference in New York, NY, vom 17. bis 19. September 2024, angekündigt. Das Management des Unternehmens wird am Donnerstag, den 19. September 2024, um 10:55 Uhr EDT an einem Feuerseitengespräch teilnehmen, zudem wird es Einzelgespräche mit Investoren geben.
Die Veranstaltung bietet CorMedix die Möglichkeit, seinen Fokus auf die Entwicklung und Vermarktung therapeutischer Produkte zur Prävention und Behandlung lebensbedrohlicher Erkrankungen und Zustände zu präsentieren. Investoren und Interessierte können über einen bereitgestellten Link auf einen Live-Webcast des Feuerseitengesprächs zugreifen, eine Aufzeichnung wird später auf der Unternehmenswebsite im Abschnitt 'Veranstaltungen und Präsentationen' verfügbar sein.
- None.
- None.
BERKELEY HEIGHTS, N.J., Sept. 13, 2024 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases, today announced that management will be participating in a fireside chat and investor meetings at the 2024 Cantor Healthcare Conference, being held in New York, NY on September 17 – 19, 2024.
Cantor Global Healthcare Conference
| Date: | Thursday, September 19, 2024 | |
| Time: | 10:55AM EDT | |
| Format: | Fireside Chat and 1x1 Meetings | |
| Webcast: | Click Link | |
A replay of the fireside chat will also be available in the “Events and Presentations” page on the investor relations portion of the Company’s website at: www.cormedix.com
About CorMedix
CorMedix Inc. is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases. The Company is focused on commercializing its lead product DefenCath®, which was approved by the FDA on November 15, 2023. CorMedix commercially launched DefenCath in inpatient settings in April 2024 and in outpatient settings in July 2024. CorMedix also intends to develop DefenCath as a catheter lock solution for use in other patient populations. For more information visit: www.cormedix.com.
Investor Contact:
Dan Ferry
Managing Director
LifeSci Advisors
daniel@lifesciadvisors.com
(617) 430-7576
FAQ
When is CorMedix (CRMD) presenting at the Cantor Global Healthcare Conference?
What type of presentation will CorMedix (CRMD) give at the Cantor conference?
Where can investors watch CorMedix's (CRMD) presentation at the Cantor conference?
What is the focus of CorMedix (CRMD) as a biopharmaceutical company?
